Equities

Zhangzhou Pientzehuang Pharmaceutical Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Zhangzhou Pientzehuang Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)170.00
  • Today's Change-0.44 / -0.26%
  • Shares traded6.96m
  • 1 Year change-17.52%
  • Beta1.3666
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Forecasts data is unavailable for this security.

Consensus recommendation

  • 20-Feb-25
  • 20-Nov-25
  • 18-Dec-25
  • 15-Jan-26
  • 05-Feb-26
Select bar for recommendation details.
Recommendations05-Feb-26
Buy1
Outperform6
Hold2
Sell2
Strong Sell0

Share price forecast in CNY

The 9 analysts offering 12 month price targets for Zhangzhou Pientzhng Phrmctcl Co Ltd have a median target of 240.00, with a high estimate of 298.00 and a low estimate of 145.00. The median estimate represents a 41.18% increase from the last price of 170.00.
High75.3%298.00
Med41.2%240.00
Low-14.7%145.00

Dividends in CNY

In 2024, Zhangzhou Pientzehuang Pharmaceutical Co Ltd reported a dividend of 2.97 CNY, which represents a 28.02% increase over last year. The 9 analysts covering the company expect dividends of 2.55 CNY for the upcoming fiscal year, a decrease of 14.04%.
Note: The percentage change is calculated using unrounded (raw) dividend values.
Div growth (TTM)28.02%
More ▼

Earnings history & estimates in CNY

On Oct 17, 2025, Zhangzhou Pientzhng Phrmctcl Co Ltd reported 3rd quarter 2025 earnings of 1.14 per share.
The next earnings announcement is expected on Apr 30, 2026.
Average growth rate+43.96%
Zhangzhou Pientzhng Phrmctcl Co Ltd reported annual 2024 earnings of 4.93 per share on Jan 23, 2025.
Average growth rate+16.67%
More ▼

Revenue history & estimates in CNY

Zhangzhou Pientzehuang Pharmaceutical., Ltd had 3rd quarter 2025 revenues of 2.05bn. This missed the 2.88bn estimate of the one analyst following the company. This was 35.19% below the prior year's 3rd quarter results.
Average growth rate-4.76%
Zhangzhou Pientzehuang Pharmaceutical., Ltd had revenues for the full year 2024 of 10.79bn. This was 7.25% above the prior year's results.
Average growth rate+13.63%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.